Cover Image
市場調查報告書

男性不孕症醫療全球市場(技法□區域別) - 市場規模、市佔率、全球動向、企業檔案資料、需求、考察、分析、調查、報告、機會、市場區塊以及預測

Global Male Infertility Market (Techniques and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2012 - 2020

出版商 Allied Market Research 商品編碼 305978
出版日期 內容資訊 英文 80 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
男性不孕症醫療全球市場(技法□區域別) - 市場規模、市佔率、全球動向、企業檔案資料、需求、考察、分析、調查、報告、機會、市場區塊以及預測 Global Male Infertility Market (Techniques and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2012 - 2020
出版日期: 2014年04月01日 內容資訊: 英文 80 Pages
簡介

即使1年不採取任何避孕手段,對方女性仍無法受孕的男性能力障礙被定義為男性不孕症,佔了整體不孕症的2成,在生活習慣的變化、老化、環境等因素為主要背景下,今後恐將持續增加,預估其相關市場今後將以4.9%的年複合成長率成長,在2020年達到3億150萬美元的規模。

本報告關注男性不孕症醫療的全球市場,以技法及區域別分析預測今後的價額變化,並彙集發展的促進、限制因素、技術研究動向、競爭環境、主要參與企業等。

第1章 簡介

  • 主要成果
  • 調查方法
    • 二次情報調查
    • 主要情報取材
    • 分析工具及模式

第2章 報告摘要

第3章 市場規模測定

  • 市場定義
    • 不孕症醫療的基礎知識
      • 外科手術
        • 精索靜脈曲張切除術
        • 其他外科手術方法
      • 性交時問題的治療
        • 勃起障礙
        • 早洩
      • 荷爾蒙療法
        • 荷爾蒙製劑
        • 非荷爾蒙製劑
      • 輔助生育技術(ART:assisted reproductive technology)
        • 睪丸微針抽取術(FNA:fine-needle aspiration)
        • 顯微副睪精子抽取術(MESA:microsurgical epididymal sperm aspiration)
        • 睪丸取精術(TESE:testicular sperm extraction)
        • 睪丸穿刺精子吸取術(TESA:testicular sperm aspiration)
      • 逆行性射精與洩精障礙的治療
      • 輸精管結紮逆轉手術(輸精管吻合手術)
      • 「輸精管結紮手術」對「輔助生育技術」
  • 男性不孕症醫療市場促進因素
    • 生活習慣問題
    • 環境因子
    • 技術進步
    • 物理原因
    • 不孕率的上昇
    • 高齡化
  • 男性不孕症醫療市場限制因素
    • 重覆治療失敗的影響
    • 社會禁忌
  • 課題與機會
    • 醫療旅遊
    • 認知度提高可能帶動市場成長
  • 需求分析
    • 不孕夫婦的數值(男女比)
    • 選擇不孕症診斷的夫婦人數
    • 體外受孕治療(IVF)的人口總數
    • 體外受孕治療的成功率
  • 男性不孕症診斷的市場規模
    • 全球市場 - 治療方法別
    • 不孕症治療方法的全球市場 - 區域別
    • 男性不孕症治療的全球市場規模

第4章 考察與對應 - 男性不孕症與體外受孕

  • 男性不孕症的原因
  • 男性不孕症的評價
  • 精液解析
    • 實驗室試驗
    • 血液檢查
    • 基因檢查
    • 其他試驗
  • 男性不孕症的治療
    • 生殖系統堵塞
    • 性腺激素治療
    • 精索靜脈曲張
    • 其他
  • 男性不孕症的輔助生育技術
    • 體外受孕
    • 卵子細胞質內單一精子顯微注射(ICSI)
    • 睪丸取精術
    • 輔助生育技術的限制
    • 不孕症治療期間的精神支持

第5章 精液解析法 - 市場規模及分析

  • DNA斷裂片分析法
    • 簡介
    • 進行DNA斷裂片分析法的時期與理由
    • 試驗結果的一致性與準確性、以及輔助生育技術選定的重要性
    • 可使用於精子DNA解析的試驗法
      • 精子染色質結構解析(SCSA:sperm chromatin structure assay)
      • TUNEL解析
      • Halo試驗
      • 慧星分析法
      • 原因不明不孕症的治療
    • DNA檢查的優點
    • 精子DNA損傷與生育結果
    • 限制
    • 男性不孕症DNA斷裂片分析的全球市場 - 區域別:2012-2020年(單位:100萬美元)
  • 氧化壓力分析
    • 活性含氧物種誘發DNA損傷及細胞凋亡
    • 氧化壓力的理由
    • 生活習慣的變化
      • 酒精攝取
      • 抽菸
      • 心理壓力
    • 老化
    • 感染 - 男性副性腺感染症
    • 環境因子
      • 電磁放射線
      • 毒物、藥物
      • 醫原性因子
      • 化學療法、藥劑
      • 精索靜脈曲張
    • 進行氧化壓力分析的時期與理由
    • 試驗結果的一致性與準確性、以及輔助生育技術選定的重要性
    • 可使用於氧化壓力分析的試驗法
      • 化學發光測定
      • 脂質過氧化指標
      • 氧化DNA損傷測定
      • 其他活性含氧物種測定法
    • 男性不孕症氧化壓力分析的全球市場 - 區域別:2012-2020年(單位:100萬美元)
  • 精子穿透力分析
    • 試驗結果的一致性與準確性、以及輔助生育技術選定的重要性
      • 試驗理由
      • 精子穿透力試驗
      • 精子黏液穿透力試驗
      • 精子穿透力分析
    • 男性不孕症精子穿透力分析的全球市場 - 區域別:2012-2020年(單位:100萬美元)
  • 電腦輔助精液分析(CASA)
    • 試驗結果的一致性與準確性、以及輔助生育技術選定的重要性
    • 電腦輔助精液分析的功能
    • 電腦輔助精液分析的全球市場 - 區域別:2012-2020年(單位:100萬美元)
  • 精子凝集試驗
    • 試驗結果的一致性與準確性、以及輔助生育技術選定的重要性
      • MAR試驗
      • 免疫珠結合
      • 診斷
    • 男性不孕症精子凝集試驗的全球市場 - 區域別:2012-2020年(單位:100萬美元)
  • 顯微鏡檢查
    • 試驗結果的一致性與準確性、以及輔助生育技術選定的重要性
      • 精子濃度
    • 男性不孕症顯微鏡檢查的全球市場 - 區域別:2012-2020年(單位:100萬美元)
  • 其他
    • 試驗結果的一致性與準確性、以及輔助生育技術選定的重要性
    • 其他男性不孕症醫療的全球市場 - 區域別:2012-2020年(單位:100萬美元)

第6章 男性不孕症醫療的全球市場 - 區域別(2012-2020年)

  • 北美
  • 歐洲
  • 亞太地區
  • 其他地區

第7章 企業檔案資料(企業概要、速覽、業績表現)

  • EMD Serono, Inc.
  • Cadila Healthcare Ltd.(ZydusCadila group)
  • ASKA pharmaceuticals, Inc.
  • Intas pharmaceuticals Ltd.
  • Pantarhei Bioscience B.V.
  • Cordex Pharma, Inc.
  • Halotech DNA SL
  • SCSA diagnostics, Inc.
  • Andrology solutions
  • Access Pharmaceuticals, Inc.
目錄
Product Code: ME 14241

The male infertility market is expected to grow to $301.5 million by 2020 with a CAGR of 4.9% during 2013-2020. Male infertility is defined as the inability of a male to impregnate his female partner after a year of unprotected intercourse. 20% of the total infertility is due to male factors. The major factors driving the male infertility market are the change in lifestyle, increasing age, environmental effects, etc., and these factors are majorly contributing to the rise in male infertility levels.

The major limitation experienced in the male infertility market is due to repeated treatment failures leading to an emotional impact on the patient. The repeated failures would compel most patients to discontinue the treatment. The other limitation is the social taboo. Out of 32-40% infertile men, only 15% of the men opt for the treatment for infertility due to the embarrassment, guilt, etc.

The opportunity driving the market is medical tourism and increase in awareness about male infertility. The treatment for male infertility is expensive; however, the cost of the treatment is expected to decrease with the advancement in treatment technologies. The other factor that may drag the prices lower would be the patients*嚚-expectations for cost effective treatments. These factors would drive the male infertility market.

Male Infertility Semen Analysis Techniques Market Analysis

The male infertility techniques market is segmented into DNA fragmentation technique, oxidative stress analysis, microscopic examination, sperm penetration assay, sperm agglutination, computer assisted semen analysis and others. The DNA fragmentation is an emerging technique; it is currently being used as a routine technique in the developed nations. However, it is yet to come into routine analysis in the labs of the developing nations, as cost being the major hindrance in their usage.

Male Infertility Geographic Market Analysis

The male infertility market is segmented into North America, Europe, Asia Pacific and RoW. The North American market is the dominating market with the highest revenue, followed by the Asia pacific market. The Asia pacific market and RoW region are expected to have the highest potential for growth in the analysis period. This is due to the adoption of the new techniques in the treatment of male infertility, such as DNA fragmentation and computer assisted semen analysis. The growth in these regions can also be accredited to the rising infertility levels and awareness about infertility and its treatments.

Competitive Landscape

The companies profiled in this report are ASKA Pharmaceutical Co. Ltd, ZydusCadila Healthcare Limited, Access Pharmaceuticals, Inc., Intas Pharmaceuticals Ltd., Pantarhei Bioscience B, Cordex Pharma, Inc., Merck Serono, Halotech DNA SL, SCSA diagnostics, Andrology Solutions.

High Level Analysis

The report analyzes various techniques used in the treatment of male infertility problems. The microscopic examination segment occupied the highest share in the male infertility techniques market in 2012. This is due to its routine use in the diagnosing of male infertility problems, as it is a basic test. DNA fragmentation segment is expected to have the highest market share by 2020, due to its accurate test results that help physicians to diagnose exact issues and suggest appropriate treatments that lead couples to conceive.

KEY BENEFITS

The report provides detailed analysis about the driving and limiting factors of the male infertility market, which would give a deeper understanding of the subject and help in taking actionable decisions.

The market size of the male infertility diagnostic and treatments will help in analyzing the market, thus helping the stakeholders understand opportunities in the male infertility market

Market share analysis of both male and female infertility treatments that allow the decision makers to gauge the market strength and make profitable investments

The report analyzes the market condition in a comprehensive and quantitative manner and forecast market trends and techniques used in male infertility treatments

Reason for the Study

  • To study the various techniques used to treat male infertility
  • To identify the benefits of the new techniques over the conventional techniques
  • To study the treatment trends in various geographic regions

KEY DELIVERABLES

The global male infertility market is segmented based on techniques and geography.

MARKET BY TECHNIQUES

  • DNA Fragmentation Technique
  • Oxidative Stress Analysis
  • Microscopic Examination
  • Sperm Penetration Assay
  • Sperm Agglutination
  • Computer Assisted Semen Analysis
  • Others

MARKET BY GEOGRAPHY

  • North America
  • Europe
  • Asia Pacific
  • RoW

Table of Contents

CHAPTER 1 - INTRODUCTION

  • 1.1. Key deliverables
  • 1.2. Research Methodology
    • 1.2.1. Secondary research
    • 1.2.2. Primary research
    • 1.2.3. Analyst tools and models

CHAPTER 2 - EXECUTIVE SUMMARY

CHAPTER 3 - MARKET SIZING

  • 3.1. Market definition
    • 3.1.1. Basics of infertility treatment techniques
      • 3.1.1.1. Surgery
        • 3.1.1.1.1. VARICOCELECTOMY
        • 3.1.1.1.2. OTHER SURGICAL METHODS
      • 3.1.1.2. Treatment for problems in intercourse.
        • 3.1.1.2.1. ERECTILE DYSFUNCTION
        • 3.1.1.2.2. PREMATURE EJACULATION
      • 3.1.1.3. Hormone treatment
        • 3.1.1.3.1. HORMONAL AGENTS
        • 3.1.1.3.2. NON-HORMONAL AGENTS
      • 3.1.1.4. ART technology
        • 3.1.1.4.1. TESTICULAR FINE NEEDLE ASPIRATION
        • 3.1.1.4.2. MICROSURGICAL EPIDIDYMAL SPERM ASPIRATION
        • 3.1.1.4.3. TESTICULAR SPERM EXTRACTION
        • 3.1.1.4.4. TESTICULAR SPERM ASPIRATION
      • 3.1.1.5. Treatment for Retrograde Ejaculation and Failure of Emission
      • 3.1.1.6. Vasectomy Reversal (Vasovasostomy)
      • 3.1.1.7. Reversal vasectomy versus ART
  • 3.2. Male infertility market drivers
    • 3.2.1. Life style issues
    • 3.2.2. Environmental factors
    • 3.2.3. Advancement in technology
    • 3.2.4. Physical causes
    • 3.2.5. Rise in infertility rates
    • 3.2.6. Age
  • 3.3. Male infertility market restraints
    • 3.3.1. Impact of repeated failures in treatments
    • 3.3.2. Social taboos
  • 3.4. Challenges and opportunities
    • 3.4.1. Medical tourism
    • 3.4.2. Increased awareness level may lead to market growth
  • 3.5. Demand analysis
    • 3.5.1. Level of infertility couples (males versus female)
    • 3.5.2. Number of couple who opt for infertility diagnostics
    • 3.5.3. Total population under IVF treatment
    • 3.5.4. Success rate for IVF treatment
  • 3.6. Male versus Female infertility treatment market
  • 3.7. Market size for male infertility diagnostics market
    • 3.7.1. Global male infertility market by techniques
    • 3.7.2. Global male infertility techniques market by geography
    • 3.7.3. Market size for male infertility treatments market

CHAPTER 4 - CONSIDERATIONS AND PROCESS - MALE INFERTILITY & IVF TREATMENT

  • 4.1. Causes of male infertility
  • 4.2. Evaluation of male infertility
  • 4.3. Semen Analysis
    • 4.3.1. Lab testing
    • 4.3.2. Blood tests
    • 4.3.3. Genetic tests
    • 4.3.4. Other tests
  • 4.4. Treatments of male infertility
    • 4.4.1. Reproductive tract blockage
    • 4.4.2. Gonadotropin treatment
    • 4.4.3. Varicocele
    • 4.4.4. Others
  • 4.5. ART for male infertility
    • 4.5.1. IVF
    • 4.5.2. ICSI
    • 4.5.3. TESE (testicular extraction of sperm)
    • 4.5.4. Limitation of ART
    • 4.5.5. Emotional support during infertility treatment

CHAPTER 5 - SEMEN ANALYSIS TECHNIQUES - MARKET SIZE AND ANALYSIS

  • 5.1. DNA fragmentation
    • 5.1.1. Introduction
    • 5.1.2. When and why is DNA fragmentation conducted
    • 5.1.3. Consistency and accuracy of data generated from the tests and importance in deciding the ART treatments
    • 5.1.4. Available tests for sperm DNA fragmentation
      • 5.1.4.1. SCSA (Sperm chromatin structure assay)
      • 5.1.4.2. TUNEL assay
      • 5.1.4.3. Halo test
      • 5.1.4.4. Comet assay
      • 5.1.4.5. Unexplained infertility treatment
    • 5.1.5. DNA testing benefits
    • 5.1.6. Sperm DNA damage and reproductive outcomes
    • 5.1.7. Limitations
    • 5.1.8. Global male infertility DNA fragmentation market by geography, 2012-2020($Million)
  • 5.2. Oxidative stress analysis
    • 5.2.1. ROS induced DNA damage and apoptosis
    • 5.2.2. Reasons for oxidative stress
    • 5.2.3. Lifestyle changes
      • 5.2.3.1. Consumption of alcohol
      • 5.2.3.2. Smoking
      • 5.2.3.3. Psychological stress
    • 5.2.4. Aging
    • 5.2.5. Infection - MAGI (Male accessory sex gland infection)
    • 5.2.6. Environmental Factors
      • 5.2.6.1. Electromagnetic radiation
      • 5.2.6.2. Toxins and chemicals
      • 5.2.6.3. Iatrogenic
      • 5.2.6.4. Chemotherapy and Drugs
      • 5.2.6.5. Varicocele
    • 5.2.7. When and why oxidative stress analysis test is conducted
    • 5.2.8. Consistency and accuracy of data generated from the tests and importance in deciding the ART treatments
    • 5.2.9. Available tests for Oxidative stress analysis
      • 5.2.9.1. Chemiluminescence
      • 5.2.9.2. Lipid peroxidation markers
      • 5.2.9.3. Measurement of oxidative DNA damage
      • 5.2.9.4. Other methods of ROS measurement
    • 5.2.10. Global male infertility oxidative stress market by geography, 2012-2020($Million)
  • 5.3. Sperm penetration assay
    • 5.3.1. Consistency and accuracy of data generated from the tests and importance in deciding the ART treatments
      • 5.3.1.1. The reasons for the tests
      • 5.3.1.2. Sperm Penetration Tests
      • 5.3.1.3. Sperm Mucus Penetration Test
      • 5.3.1.4. Sperm Penetration Assay
    • 5.3.2. Global male infertility sperm penetration assay market by geography, 2012-2020($Million)
  • 5.4. Computer assisted semen analysis
    • 5.4.1. Consistency and accuracy of data generated from the tests and importance in deciding the ART treatments
    • 5.4.2. Functions of computer assisted sperm analysis
    • 5.4.3. Global male infertility CASA market by geography, 2012-2020($Million)
  • 5.5. Sperm Agglutination
    • 5.5.1. Consistency and accuracy of data generated from the tests and importance in deciding the ART treatments
      • 5.5.1.1. MAR test
      • 5.5.1.2. Immunobead Binding
      • 5.5.1.3. Diagnosis
    • 5.5.2. Global male infertility sperm agglutination market by geography, 2012-2020($Million)
  • 5.6. Microscopic examination
    • 5.6.1. Consistency and accuracy of data generated from the tests and importance in deciding the ART treatments
      • 5.6.1.1. Sperm concentration
    • 5.6.2. Global male infertility microscopic examination market by geography, 2012-2020($Million)
  • 5.7. Others
    • 5.7.1. Consistency and accuracy of data generated from the tests and importance in deciding the ART treatments
    • 5.7.2. Global male infertility others market by geography, 2012-2020($Million)

CHAPTER 6 - GLOBAL MALE INFERTILITY MARKET BY GEOGRAPHY

  • 6.1. North America
    • 6.1.1. North American male infertility market, 2012-2020
  • 6.2. Europe
    • 6.2.1. Europe male infertility market, 2012-2020
  • 6.3. Asia pacific
    • 6.3.1. Asia pacific male infertility market, 2012-2020
  • 6.4. RoW
    • 6.4.1. RoW male infertility market, 2012-2020

CHAPTER 7 - COMPANY PROFILES

  • 7.1. EMD Serono, Inc.
    • 7.1.1. Company overview
    • 7.1.2. Company snapshot
    • 7.1.3. Business performance
  • 7.2. Cadila Healthcare Ltd.(ZydusCadila group)
    • 7.2.1. Company overview
    • 7.2.2. Company snapshot
  • 7.3. ASKA pharmaceuticals, Inc.
    • 7.3.1. Company overview
    • 7.3.2. Company snapshot
    • 7.3.3. Business performance
    • 7.3.4. Strategic moves and developments
  • 7.4. Intas pharmaceuticals Ltd.
    • 7.4.1. Company overview
    • 7.4.2. Company snapshot
    • 7.4.3. Business performance
  • 7.5. Pantarhei Bioscience B.V.
    • 7.5.1. Company overview
    • 7.5.2. Company snapshot
  • 7.6. Cordex Pharma, Inc.
    • 7.6.1. Company overview
    • 7.6.2. Company snapshot
  • 7.7. Halotech DNA SL
    • 7.7.1. Company overview
    • 7.7.2. Company snapshot
    • 7.7.3. Financial Performance
  • 7.8. SCSA diagnostics, Inc.
    • 7.8.1. Company overview
    • 7.8.2. Company snapshot
    • 7.8.3. Financial Performance
  • 7.9. Andrology solutions
    • 7.9.1. Company overview
    • 7.9.2. Company snapshot
  • 7.10. Access Pharmaceuticals, Inc.
    • 7.10.1. Company overview
    • 7.10.2. Company snapshot
    • 7.10.3. Business performance

LIST OF TABLES:

  • TABLE 1: GLOBAL MALE INFERTILITY TECHNIQUES MARKET BY GEOGRAPHY, 2012-2020 ($MILLION)
  • TABLE 2: GLOBAL MALE INFERTILITY MARKET BY TECHNIQUES,2012-2020 ($MILLION)
  • TABLE 3: GLOBAL MALE INFERTILITY TECHNIQUES MARKET BY GEOGRAPHY, 2012-2020 ($MILLION)
  • TABLE 4: GLOBAL MALE INFERTILITY DNA FRAGMENTATION MARKET BY GEOGRAPHY, 2012-2020 ($MILLION)
  • TABLE 5: GLOBAL MALE INFERTILITY OXIDATIVE STRESS MARKET BY GEOGRAPHY, 2012-2020 ($MILLION)
  • TABLE 6: GLOBAL MALE INFERTILITY SPERM PENETRATION ASSAY MARKET BY GEOGRAPHY, 2012-2020 ($MILLION)
  • TABLE 7: GLOBAL MALE INFERTILITY CASA MARKET BY GEOGRAPHY, 2012-2020 ($MILLION)
  • TABLE 8: GLOBAL MALE INFERTILITY SPERM AGGLUTINATION MARKET BY GEOGRAPHY, 2012-2020 ($MILLION)
  • TABLE 9: GLOBAL MALE INFERTILITY MICROSCOPIC EXAMINATION MARKET BY GEOGRAPHY, 2012-2020 ($MILLION)
  • TABLE 10: GLOBAL MALE INFERTILITY OTHERS MARKET BY GEOGRAPHY, 2012-2020 ($MILLION)
  • TABLE 11: NORTH AMERICAN MALE INFERTILITY MARKET, 2012-2020 ($MILLION)
  • TABLE 12: EUROPE MALE INFERTILITY MARKET, 2012-2020 ($MILLION)
  • TABLE 13: ASIA PACIFIC MALE INFERTILITY MARKET, 2012-2020 ($MILLION)
  • TABLE 14: ROW MALE INFERTILITY MARKET, 2012-2020 ($MILLION)
  • TABLE 15: EMD SERONO, INC BUSINESS SNAPSHOT
  • TABLE 16: ASKA PHARMACEUTICALS, INC BUSINESS SNAPSHOT
  • TABLE 17: ASKA PHARMACEUTICALS, INC BUSINESS SNAPSHOT
  • TABLE 18: ASKA PHARMACEUTICALS, INC BUSINESS SNAPSHOT
  • TABLE 19: PANTARHEI BIOSCIENCE B.V. BUSINESS SNAPSHOT
  • TABLE 20: CORDEX PHARMA, INC. BUSINESS SNAPSHOT
  • TABLE 21: HALOTECH DNA SL BUSINESS SNAPSHOT
  • TABLE 22: SCSA DIAGNOSTICS, INC. BUSINESS SNAPSHOT
  • TABLE 23: ANDROLOGY SOLUTIONS BUSINESS SNAPSHOT
  • TABLE 24: ACCESS PHARMACEUTICALS, INC. BUSINESS SNAPSHOT

LIST OF FIGURES:

  • FIG. 1: TYPES OF MALE DISORDERS
  • FIG. 2: CONVENTIONAL, CURRENT AND ADVANCED TREATMENTS FOR MALE INFERTILITY
  • FIG. 3: PERCENTAGE OF RETRIEVALS WHICH RESULTED IN LIVE BIRTHS AMONG COUPLES WITH DIAGNOSED MALE FACTOR INFERTILITY USING IVF WITH ICSI (2010)
  • FIG. 4: MARKET SHARE OF MALE AND FEMALE INFERTILITY TREATMENT 2013 AND 2020
  • FIG. 5: MARKET SHARE OF MALE VERSUS FEMALE INFERTILITY TREATMENT MARKET (PERCENTAGE SHARE - 2013 TO 2020)
  • FIG. 6: MARKET SIZE FOR MALE INFERTILITY TREATMENTS MARKET, 2013 - 2020 ($MILLION)
  • FIG. 7: LEVEL OF FRAGMENTED DNA
  • FIG. 8: NUMBER OF DELIVERIES WITH OR WITHOUT MEASURING FRAGMENTATION
  • FIG. 9: SALES BY REGION, 2012
  • FIG. 10: HALOTECH DNA SL REVENUE BY YEAR (2012 - 2013)
  • FIG. 11: SCSA DIAGNOSTICS, INC. REVENUE BY YEAR (2012 - 2013)
  • FIG. 12: ACCESS PHARMACEUTICALS, INC. REVENUE BY YEAR (2011 - 2012)
Back to Top